TERT promoter mutations in melanoma survival

International Journal of Cancer

Volumn 139, Issue 1, 2016, Pages 75-84

  Nagore, Eduardo ^a   Heidenreich, Barbara ^b   Rachakonda, Sívaramakrishna ^b   Garcia Casado, Zaida ^a   Requena, Celia ^a   Soriano, Virtudes ^a   Frank, Christoph ^b   Traves, Victor ^a   Quecedo, Esther ^c   Sanjuan Gimenez, Josefa ^c   Hemminki, Kari ^b,d   Landi, Maria Teresa ^e   Kumar, Rajiv ^b  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HOSPITAL ARNAU DE VILANOVA   (Spain)

^d LUND UNIVERSITY   (Sweden)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

BRAF mutations; disease free survival; melanoma; melanoma specific survival; TERT promoter mutations

Indexed keywords

B RAF KINASE; DABRAFENIB; IMATINIB; TELOMERASE; VEMURAFENIB; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; TERT PROTEIN, HUMAN; TUMOR MARKER;

AGE; ALLELE; ARTICLE; BRAF GENE; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CARRIER; DISEASE FREE SURVIVAL; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOMA; NRAS GENE; PATIENT RISK; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; ADULT; AGED; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; GTP PHOSPHOHYDROLASES; HUMANS; KAPLAN-MEIER ESTIMATE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS B-RAF; TELOMERASE;

EID: 84959480782     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30042     Document Type: Article

References (44)

1. Tsao H, Chin L, Garraway LA, et al., Melanoma: from mutations to medicine. Genes Dev 2012; 26: 1131-55.
2. Das Thakur M, Stuart DD., The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 2013; 73: 6106-10.
3. Long GV, Fung C, Menzies AM, et al., Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nat Commun 2014; 5: 5694.
4. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., Signatures of mutational processes in human cancer. Nature 2013; 500: 415-21.
5. Hodis E, Watson IR, Kryukov GV, et al., A landscape of driver mutations in melanoma. Cell 2012; 150: 251-63.
6. Krauthammer M, Kong Y, Ha BH, et al., Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 2012; 44: 1006-14.
7. Berger MF, Hodis E, Heffernan TP, et al., Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012; 485: 502-6.
8. Gartner JJ, Parker SC, Prickett TD, et al., Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proc Natl Acad Sci USA 2013; 110: 13481-6.
9. Wei X, Walia V, Lin JC, et al., Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat Genet 2011; 43: 442-6.
10. Aydin IT, Melamed RD, Adams SJ, et al., FBXW7 mutations in melanoma and a new therapeutic paradigm. J Natl Cancer Inst 2014; 106: dju107.
11. Stark MS, Woods SL, Gartside MG, et al., Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat Genet 2012; 44: 165-9.
12. Nikolaev SI, Rimoldi D, Iseli C, et al., Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012; 44: 133-9.
13. The Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015; 161: 1681-96.
14. Denisova E, Heidenreich B, Nagore E, et al., Frequent DPH3 promoter mutations in skin cancers. Oncotarget 2015; 6: 35922-30.
15. Horn S, Figl A, Rachakonda PS, et al., TERT promoter mutations in familial and sporadic melanoma. Science 2013; 339: 959-61.
16. Heidenreich B, Nagore E, Rachakonda PS, et al., Telomerase reverse transcriptase promoter mutations in primary cutaneous melanoma. Nat Commun 2014; 5: 3401.
17. Shain AH, Yeh I, Kovalyshyn I, et al., The genetic evolution of melanoma from precursor lesions. N Engl J Med 2015; 373: 1926-36.
18. Populo H, Boaventura P, Vinagre J, et al., TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol 2014; 134: 2251-7.
19. Griewank KG, Murali R, Puig-Butille JA, et al., TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma. J Natl Cancer Inst 2014; 106, doi: 10.1093/jnci/dju246.
20. Nagore E, Heidenreich B, Requena C, et al., TERT promoter mutations associate with fast growing melanoma. Pigment Cell Melanoma Res 2015; 29: 236-8.
21. Rachakonda PS, Hosen I, de Verdier PJ, et al., TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. Proc Natl Acad Sci USA 2013; 110: 17426-31.
22. Macerola E, Loggini B, Giannini R, et al., Coexistence of TERT promoter and BRAF mutations in cutaneous melanoma is associated with more clinicopathological features of aggressiveness. Virchows Arch 2015; 467: 177-84.
23. Bell RJ, Rube HT, Kreig A, et al., Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. Science 2015; 348: 1036-9.
24. Charlot C, Dubois-Pot H, Serchov T, et al., A review of post-translational modifications and subcellular localization of Ets transcription factors: possible connection with cancer and involvement in the hypoxic response. Methods Mol Biol 2010; 647: 3-30.
25. Xing M, Liu R, Liu X, et al., BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014; 32: 2718-26.
26. Flaherty KT, Hodi FS, Fisher DE., From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer 2012; 12: 349-61.
27. Simon M, Hosen I, Gousias K, et al., TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol 2015; 17: 45-52.
28. Hosen I, Rachakonda PS, Heidenreich B, et al., TERT promoter mutations in clear cell renal cell carcinoma. Int J Cancer 2015; 136: 2448-52.
29. Spiegl-Kreinecker S, Lotsch D, Ghanim B, et al., Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis. Neuro Oncol 2015; 17: 1231-40.
30. Hosen I, Rachakonda PS, Heidenreich B, et al., Mutations in TERT promoter and FGFR3 and telomere length in bladder cancer. Int J Cancer 2015; 137: 1621-9.
31. Mosrati MA, Willander K, Falk IJ, et al., Association between TERT promoter polymorphisms and acute myeloid leukemia risk and prognosis. Oncotarget 2015; 6: 25109-20.
32. Yoo SS, Do SK, Choi JE, et al., TERT polymorphism rs2853669 influences on lung cancer risk in the Korean population. J Korean Med Sci 2015; 30: 1423-8.
33. Shadrina AS, Boyarskikh UA, Oskina NA, et al., TERT polymorphisms rs2853669 and rs7726159 influence on prostate cancer risk in Russian population. Tumour Biol 2015; 36: 841-7.
34. Killela PJ, Reitman ZJ, Jiao Y, et al., TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 2013; 110: 6021-6.
35. Ma X, Gong R, Wang R, et al., Recurrent TERT promoter mutations in non-small cell lung cancers. Lung Cancer 2014; 86: 369-73.
36. Stoehr R, Taubert H, Zinnall U, et al., Frequency of TERT promoter mutations in prostate cancer. Pathobiology 2015; 82: 53-7.
37. Xu D, Dwyer J, Li H, et al., Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 2008; 283: 23567-80.
38. Hsu CP, Hsu NY, Lee LW, et al., Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter-effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 2006; 42: 1466-74.
39. Heidenreich B, Rachakonda PS, Hemminki K, et al., TERT promoter mutations in cancer development. Curr Opin Genet Dev 2014; 24: 30-7.
40. Stern JL, Theodorescu D, Vogelstein B, et al., Mutation of the TERT promoter, switch to active chromatin, and monoallelic TERT expression in multiple cancers. Genes Dev 2015; 29: 2219-24.
41. Li Y, Zhou QL, Sun W, et al., Non-canonical NF-kappaB signalling and ETS1/2 cooperatively drive C250T mutant TERT promoter activation. Nat Cell Biol 2015; 17: 1327-38.
42. Chiba K, Johnson JZ, Vogan JM, et al., Cancer-associated TERT promoter mutations abrogate telomerase silencing. Elife 2015; 4: e07918.
43. Ding Z, Wu CJ, Jaskelioff M, et al., Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 2012; 148: 896-907.
44. Bagheri S, Nosrati M, Li S, et al., Genes and pathways downstream of telomerase in melanoma metastasis. Proc Natl Acad Sci USA 2006; 103: 11306-11.